{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:04:57Z","timestamp":1790485497827,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40272-014-0079-z","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T07:34:13Z","timestamp":1404977653000},"page":"275-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Clinical Features and Pharmacotherapy of Childhood Monoamine Neurotransmitter Disorders"],"prefix":"10.1007","volume":"16","author":[{"given":"J.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J. R.","family":"Heales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"79_CR1","first-page":"629","volume":"42","author":"DS Goldstein","year":"1998","unstructured":"Goldstein DS. Catecholamines in the periphery. Overview Adv Pharmacol. 1998;42:629\u201339.","journal-title":"Overview Adv Pharmacol"},{"key":"79_CR2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0024-3205(97)01166-1","volume":"62","author":"O Yildiz","year":"1998","unstructured":"Yildiz O, Smith JR, Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci. 1998;62:1723\u201332.","journal-title":"Life Sci"},{"key":"79_CR3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12098-009-0138-6","volume":"76","author":"E Fernandez-Alvarez","year":"2009","unstructured":"Fernandez-Alvarez E. Movement disorders in children: recent advances in management. Indian J Pediatr. 2009;76:531\u20136.","journal-title":"Indian J Pediatr"},{"key":"79_CR4","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351:2498\u2013508.","journal-title":"N Engl J Med"},{"key":"79_CR5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.22685","volume":"71","author":"J Friedman","year":"2012","unstructured":"Friedman J, Roze E, Abdenau JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71:520\u201330.","journal-title":"Ann Neurol"},{"key":"79_CR6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0165-6147(94)90323-9","volume":"15","author":"P Seeman","year":"1994","unstructured":"Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmcol Sci. 1994;15:264\u201370.","journal-title":"Trends Pharmcol Sci"},{"key":"79_CR7","first-page":"1","volume-title":"Monoamine oxidase inhibitors in neurological disease","author":"KN Westlund","year":"1994","unstructured":"Westlund KN. The distribution of monoamine oxidases A and B in normal human brain. In: Leiberman A, Olanow CW, Youdim MBH, Tipton K, editors. Monoamine oxidase inhibitors in neurological disease. New York: Marcel Dekker; 1994. p. 1\u201320."},{"key":"79_CR8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10545-009-1076-1","volume":"32","author":"C Manegold","year":"2009","unstructured":"Manegold C, Hoffmann GF, Degen I, et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow up. J Inherit Metab Dis. 2009;32:371\u201380.","journal-title":"J Inherit Metab Dis"},{"key":"79_CR9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/ern.10.44","volume":"10","author":"WV Bobo","year":"2010","unstructured":"Bobo WV, Shelton RC. Efficacy, safety and tolerability of SymbyaxAR for acute-phase management of treatment-resistant depression. Expert Rev Neurother. 2010;10:651\u201370.","journal-title":"Expert Rev Neurother"},{"key":"79_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2009.01.010","volume":"97","author":"GF Allen","year":"2009","unstructured":"Allen GF, Land JM, Heales SJR. A new perspective on the treatment of aromatic l-amino acid decarboxylase deficiency. Mol Genet Metab. 2009;97:6\u201314.","journal-title":"Mol Genet Metab"},{"issue":"Pt 7","key":"79_CR11","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/brain\/aws122","volume":"135","author":"M Grapp","year":"2012","unstructured":"Grapp M, Just IA, Linnankivi T, et al. Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency. Brain. 2012;135(Pt 7):2022\u201331.","journal-title":"Brain"},{"key":"79_CR12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ymgme.2012.01.013","volume":"105","author":"F Porta","year":"2012","unstructured":"Porta F, Mussa A, Concolino D, et al. Dopamine agonists in dihydropteridine reductase deficiency. Mol Genet Metab. 2012;105:582\u20134.","journal-title":"Mol Genet Metab"},{"key":"79_CR13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.20055","volume":"55","author":"YT Chang","year":"2004","unstructured":"Chang YT, Sharma R, Marsh JL, et al. Levodopa responsive aromatic l-amino acid decarboxylase deficiency. Ann Neurol. 2004;55:435\u20138.","journal-title":"Ann Neurol"},{"key":"79_CR14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jnnp.53.7.569","volume":"53","author":"R Surtees","year":"1990","unstructured":"Surtees R, Hyland K. l-3,4-dihydroxyphenylalanine (Levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J Neurol Neurosurg Psychiatry. 1990;53:569\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"79_CR15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet Neurol. 2010;376:1417\u201327.","journal-title":"Lancet Neurol"},{"key":"79_CR16","first-page":"1","volume":"32","author":"M Segawa","year":"2009","unstructured":"Segawa M. Autosomal dominant GTP cyclohydrolase 1 (AD GCH1) deficiency (Segawa disease, dystonia 5, DYT 5). Chang Gung Med J. 2009;32:1\u201311.","journal-title":"Chang Gung Med J"},{"key":"79_CR17","doi-asserted-by":"crossref","unstructured":"Furukawa Y, Pagon RA, Adam MP, et al. GTP cyclohydrolase 1-deficient dopa-responsive dystonia. Gene reviews. Seattle: University of Washington; 1993\u20132013.","DOI":"10.1093\/brain\/awu325"},{"key":"79_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.braindev.2010.10.015","volume":"22","author":"M Segawa","year":"2011","unstructured":"Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev. 2011;22:195\u2013201.","journal-title":"Brain Dev"},{"key":"79_CR19","first-page":"215","volume":"14","author":"M Segawa","year":"1976","unstructured":"Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol. 1976;14:215\u201333.","journal-title":"Adv Neurol"},{"key":"79_CR20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/jnnp.2008.155861","volume":"80","author":"I Trender-Gerhard","year":"2009","unstructured":"Trender-Gerhard I, Sweeney MG, et al. Autosomal-dominant GTPCH1-deficiency DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry. 2009;80:839\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"79_CR21","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3346\/jkms.2011.26.9.1244","volume":"26","author":"JH Lee","year":"2011","unstructured":"Lee JH, Ki CS, Kim DS, et al. Dopa-responsive dystonia with a novel initiation mutation in the GCH1 gene misdiagnoses as cerebral palsy. J Korean Med Sci. 2011;26:1244\u20136.","journal-title":"J Korean Med Sci"},{"key":"79_CR22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pediatrneurol.2004.03.017","volume":"31","author":"MMS Jan","year":"2004","unstructured":"Jan MMS. Misdiagnosis in children with Dopa responsive dystonia. J Pediatr Neurol. 2004;31:298\u2013303.","journal-title":"J Pediatr Neurol"},{"key":"79_CR23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1469-8749.2010.03619.x","volume":"52","author":"RC Dale","year":"2010","unstructured":"Dale RC, Melchers A, Fung VS, et al. Familial paroxysmal exercise-induced dystonia: atypical presentation of autosomal dominant GTP-cyclohydrolase 1 deficiency. Dev Med Child Neurol. 2010;52:583\u20136.","journal-title":"Dev Med Child Neurol"},{"key":"79_CR24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2004.07.010","volume":"83","author":"R Saunders-Pullman","year":"2004","unstructured":"Saunders-Pullman R, Blau N, Hyland K, et al. Phenylalanine loading as a diagnostic test for DRD interpreting the utility of the test. Mol Genet Metab. 2004;83:207\u201312.","journal-title":"Mol Genet Metab"},{"key":"79_CR25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(11)70141-7","volume":"10","author":"MA Kurian","year":"2011","unstructured":"Kurian MA, Gissen P, Smith M, et al. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10:721\u201333.","journal-title":"Lancet Neurol"},{"key":"79_CR26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2012.03.003","volume":"46","author":"E Lopez-Laso","year":"2012","unstructured":"Lopez-Laso E, Beyer K, Opladen T, et al. Dyskinesias as a limiting factor in the treatment of Segawa disease. Pediatr Neurol. 2012;46:404\u20136.","journal-title":"Pediatr Neurol"},{"key":"79_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1353-8020(00)00084-5","volume":"8","author":"WJ Hwang","year":"2008","unstructured":"Hwang WJ, Calne JKC, Tsui R, et al. The long-term response to levodopa in dopa-responsive dystonia. Parkinson Relat Disord. 2008;8:1\u20135.","journal-title":"Parkinson Relat Disord"},{"key":"79_CR28","doi-asserted-by":"crossref","first-page":"41150","DOI":"10.1074\/jbc.M102237200","volume":"276","author":"C Sumi-Ichinose","year":"2001","unstructured":"Sumi-Ichinose C, Urano F, Kuroda R, et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. A study from 6-pyruvolytetrahydrobiopterin synthase knockout mice. J Biol Chem. 2001;276:41150\u201360.","journal-title":"J Biol Chem"},{"key":"79_CR29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/clinchem\/47.3.477","volume":"47","author":"L Bonafe","year":"2001","unstructured":"Bonafe L, Thony B, Leimbacjer W, et al. Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem. 2001;47:477\u201385.","journal-title":"Clin Chem"},{"key":"79_CR30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2008.01.003","volume":"94","author":"GA Horvath","year":"2008","unstructured":"Horvath GA, Stockler-Ipsiroglu SG, Salvarinova-Zivkovi R, et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: Evident of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab. 2008;94:127\u201331.","journal-title":"Mol Genet Metab"},{"key":"79_CR31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.23329","volume":"25","author":"T Opladen","year":"2011","unstructured":"Opladen T, Hoffmann G, Horster F, et al. Clinical and biochemical characterisation of patients with early infantile onset of autosomal recessive GTP cyclohydrolase 1 deficiency without hyperphenylalaninemia. Mov Disord. 2011;25:157\u201361.","journal-title":"Mov Disord"},{"key":"79_CR32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10545-009-1067-2","volume":"32","author":"N Longo","year":"2009","unstructured":"Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009;32:333\u201342.","journal-title":"J Inherit Metab Dis"},{"key":"79_CR33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10545-012-9506-x","volume":"35","author":"T Opladen","year":"2012","unstructured":"Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012;35:963\u201373.","journal-title":"J Inherit Metab Dis"},{"key":"79_CR34","first-page":"2417","volume":"33","author":"I Smith","year":"1983","unstructured":"Smith I, Dhondt JL. Birthweight in patients with defective biopterin metabolism. Lancet. 1983;33:2417\u201324.","journal-title":"Lancet"},{"key":"79_CR35","first-page":"157","volume":"26","author":"V Leuzzi","year":"2010","unstructured":"Leuzzi V, Carducci CA, Carducci CL, et al. Phenotypic variability, neurological outcome and genetic background of 6-pyruvoyl-tetrahydrobiopterin synthase deficiency. Clin Genet. 2010;26:157\u201361.","journal-title":"Clin Genet"},{"key":"79_CR36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ymgme.2007.10.004","volume":"93","author":"L Jaggi","year":"2008","unstructured":"Jaggi L, Zurfluh MR, Schuler A, et al. Outcome and long term follow up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab. 2008;93:295\u2013305.","journal-title":"Mol Genet Metab"},{"key":"79_CR37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1212\/WNL.0b013e3181b38983","volume":"73","author":"F Porta","year":"2009","unstructured":"Porta F, Mussa A, Concolino D, et al. Dopamine agonists in 6-pyruvoyl tetrahydrobiopterin synthase deficiency. Neurology. 2009;73:633\u20136.","journal-title":"Neurology"},{"issue":"78","key":"79_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0b013e3182452849","volume":"31","author":"P Dill","year":"2012","unstructured":"Dill P, Wagner M, Somerville A, et al. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology. 2012;31(78):29\u201332.","journal-title":"Neurology"},{"key":"79_CR39","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/brain\/awh603","volume":"128","author":"BG Neville","year":"2005","unstructured":"Neville BG, Parascandalo R, Farrugia R, et al. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain. 2005;128:2291\u20136.","journal-title":"Brain"},{"key":"79_CR40","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1212\/01.wnl.0000247274.21261.b4","volume":"67","author":"J Friedman","year":"2006","unstructured":"Friedman J, Hyland K, Blau N, et al. Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology. 2006;67:2032\u20135.","journal-title":"Neurology"},{"key":"79_CR41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1074\/jbc.M805403200","volume":"294","author":"MJ Crabtree","year":"2009","unstructured":"Crabtree MJ, Tatham Al, Al Wakeel Y, et al. Quantitative regulation of intracellular endothelila nitric-oxide synthase (eNOS) coupling by tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP-cyclohydroxylase I expression. J Biol Chem. 2009;294:1136\u201344.","journal-title":"J Biol Chem"},{"key":"79_CR42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/brain\/awq087","volume":"133","author":"MA Willemsen","year":"2010","unstructured":"Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency; a treatable disorder of brain catecholamine biosynthesis. Brain. 2010;133:1810\u201322.","journal-title":"Brain"},{"issue":"Suppl 1","key":"79_CR43","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1090-3798(13)70063-1","volume":"15","author":"R Pons","year":"2013","unstructured":"Pons R, Syrengelas D, Syrengelas A, et al. Tyrosine hydroxylase: the Greek experience. Eur J Paediatr Neurol. 2013;15(Suppl 1):S19\u201320.","journal-title":"Eur J Paediatr Neurol"},{"key":"79_CR44","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/mds.25382","volume":"28","author":"R Pons","year":"2013","unstructured":"Pons R, Syrengelas D, Youroukos S, et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord. 2013;28:1058\u201363.","journal-title":"Mov Disord"},{"key":"79_CR45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1212\/WNL.0b013e3181e620ae","volume":"75","author":"L Brun","year":"2010","unstructured":"Brun L, Ngu LH, Chang GS, et al. Clinical and biochemical features of aromatic l-amino acid decarboxylase deficiency. Neurology. 2010;75:64\u201371.","journal-title":"Neurology"},{"key":"79_CR46","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1212\/WNL.62.7.1058","volume":"62","author":"R Pons","year":"2004","unstructured":"Pons R, Ford B, Chiriboga CA, et al. Aromatic amino acid decarboxylase deficiency: clinical features, treatment, prognosis. Neurology. 2004;62:1058\u201365.","journal-title":"Neurology"},{"key":"79_CR47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejpn.2008.03.008","volume":"13","author":"H Lee","year":"2009","unstructured":"Lee H, Tsai CR, Chi CS, et al. Aromatic l-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol. 2009;13:135\u201340.","journal-title":"Eur J Paediatr Neurol"},{"key":"79_CR48","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mds.25303","volume":"28","author":"M Mastrangelo","year":"2012","unstructured":"Mastrangelo M, Caputi C, Galosi S, et al. Transdermal rotigotine in the treatment of aromatic l-amino acid decarboxylase deficiency. Mov Disord. 2012;28:556\u20137.","journal-title":"Mov Disord"},{"key":"79_CR49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2010.06742.x","volume":"114","author":"GF Allen","year":"2010","unstructured":"Allen GF, Neergheen V, Oppenheim M, et al. Pyridoxal 5\u2032phosphate deficiency causes a loss of aromatic l-amino acid decarboxylase in patient and human neuroblastoma cells, implications for aromatic l-amino acid decarboxylase and vitamin B6 deficiency states. J Neurochem. 2010;114:87\u201396.","journal-title":"J Neurochem"},{"key":"79_CR50","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/WNL.42.10.1980","volume":"42","author":"K Hyland","year":"1992","unstructured":"Hyland K, Surtees RAH, Rodeck C, et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology. 1992;42:1980\u20138.","journal-title":"Neurology"},{"key":"79_CR51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/088307389701200602","volume":"12","author":"A Maller","year":"1997","unstructured":"Maller A, Hyland K, Milstein S, et al. Aromatic l-amino acid decarboxylase deficiency: clinical feature. J Child Neurol. 1997;12:349\u201354.","journal-title":"J Child Neurol"},{"key":"79_CR52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jb\/mvh004","volume":"135","author":"N Matsuda","year":"2004","unstructured":"Matsuda N, Hayaashi H, Miyatake T, et al. Instability of the apo form of aromatic a l-amino acid decarboxylase activity in vivo and in vitro: implications for the involvement of the flexible loop that covers the active site. J Biochem. 2004;135:33\u201342.","journal-title":"J Biochem"},{"key":"79_CR53","first-page":"264","volume":"54","author":"KJ Swodoba","year":"2003","unstructured":"Swodoba KJ, Saul JP, McKenna CE, et al. Aromatic l-amino acid decarboxylase deficiency overview of clinical features and outcomes. Ann Neurol. 2003;54:264\u201370.","journal-title":"Ann Neurol"},{"key":"79_CR54","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0022-3565(25)20316-0","volume":"258","author":"IA Paterson","year":"1991","unstructured":"Paterson IA, Juorio AV, Berry MY, et al. Inhibition of monoamine oxidase-B by deprenyl potentials neuronal response to dopamine agonistics but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther. 1991;258:1019\u201326.","journal-title":"J Pharmacol Exp Ther"},{"key":"79_CR55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(96)00530-4","volume":"310","author":"AM Cho","year":"1996","unstructured":"Cho AM, Duchemin NH, Neff M, et al. Modulation of tyrosine hydroxylase and aromatic l-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur J Pharmacol. 1996;310:51\u20139.","journal-title":"Eur J Pharmacol"},{"key":"79_CR56","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1471-4159.1986.tb08511.x","volume":"46","author":"LE Dyck","year":"1986","unstructured":"Dyck LE, Dewar KM. Inhibition of aromatic l-amino decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine. J Neurochem. 1986;46:1899\u2013903.","journal-title":"J Neurochem"},{"key":"79_CR57","first-page":"134ra61","volume":"4","author":"WL Hwu","year":"2012","unstructured":"Hwu WL, Muramatsu S, Tseng SH, et al. Gene therapy for aromatic l-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4:134ra61.","journal-title":"Sci Transl Med"},{"key":"79_CR58","first-page":"218","volume":"133","author":"PB Mills","year":"2010","unstructured":"Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain. 2010;133:218\u201359.","journal-title":"Brain"},{"key":"79_CR59","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/hmg\/ddi120","volume":"14","author":"PB Mills","year":"2005","unstructured":"Mills PB, Surtees RA, Champion MP, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5\u2032 phosphate oxidase. Hum Mol Genet. 2005;14:1077\u201386.","journal-title":"Hum Mol Genet"},{"key":"79_CR60","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1073\/pnas.1101193108","volume":"108","author":"SD Reddy","year":"2011","unstructured":"Reddy SD, Rayala SK, Ohshiro K, et al. Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc Natl Acad Sci USA. 2011;108:4200\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"79_CR61","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1523\/JNEUROSCI.3718-04.2005","volume":"25","author":"DY Hwang","year":"2005","unstructured":"Hwang DY. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson\u2019s disease. J Neurosci. 2005;25:2132\u20137.","journal-title":"J Neurosci"},{"key":"79_CR62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0169-328X(03)00162-1","volume":"114","author":"D-Y Hwang","year":"2003","unstructured":"Hwang D-Y, Ardayfio P, Kang UJ, Semina EV, Kim KS. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res. 2003;114:123\u201331.","journal-title":"Brain Res Mol Brain Res"},{"key":"79_CR63","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajmg.b.32020","volume":"159","author":"K Katarzyna Derwinska","year":"2012","unstructured":"Katarzyna Derwinska K, Mierzewska H, Goszczanska A, et al. Clinical improvement of the aggressive neurobehavioral phenotype in a patient with a deletion of PITX3 and the absence of l-DOPA in the cerebrospinal fluid. Am J Med Genet B Neuropsychiatr Genet. 2012;159:236\u201342.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"79_CR64","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa1207281","volume":"368","author":"JJ Rilstone","year":"2013","unstructured":"Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine\u2013serotonin vesicular transport disease and its treatment. NEJM. 2013;368:543\u201350.","journal-title":"NEJM"},{"key":"79_CR65","first-page":"1595","volume":"119","author":"MA Kurian","year":"2009","unstructured":"Kurian MA, Zhen J, Cheng SY, et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism dystonia. J Clin Invest. 2009;119:1595\u2013603.","journal-title":"J Clin Invest"},{"key":"79_CR66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1474-4422(10)70269-6","volume":"10","author":"MA Kurian","year":"2011","unstructured":"Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol. 2011;10:54\u201362.","journal-title":"Lancet Neurol"},{"key":"79_CR67","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/brain\/awu022","volume":"137","author":"J Ng","year":"2014","unstructured":"Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. 2014;137:1107\u201319.","journal-title":"Brain"},{"key":"79_CR68","unstructured":"Henriksen FH, Yasmeen S, Skj\u00f8rringe T, et al. Atypical dopamine transporter deficiency syndrome in an adult male: molecular characterisation of new transporter variants. Program No.10.11. 2013 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience; 2013. http:\/\/www.sfn.org\/~\/media\/SfN\/Documents\/AnnualMeeting\/FinalProgram\/FullAbstractPDFs\/AbstractPDFs_Nano.ashx (Online)."},{"key":"79_CR69","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1469-8749.2007.00740.x","volume":"49","author":"A Garc\u00eda-Cazorla","year":"2007","unstructured":"Garc\u00eda-Cazorla A, Serrano M, P\u00e9rez-Due\u00f1as B, et al. Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev Med Child Neurol. 2007;49:740\u20134.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"79_CR70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/dmcn.12130","volume":"55","author":"MA Kurian","year":"2013","unstructured":"Kurian MA. What is the role of dopamine in childhood neurological disorders? Dev Med Child Neurol. 2013;55(6):493\u20134.","journal-title":"Dev Med Child Neurol"},{"issue":"S1","key":"79_CR71","first-page":"15","volume":"5","author":"J Ng","year":"2013","unstructured":"Ng J, Tuschl K, Kinali M, et al. TH gene-negative infantile onset severe dopamine deficiency syndrome: a novel neurotransmitter disorder? Dev Med Child Neurol. 2013;5(S1):15.","journal-title":"Dev Med Child Neurol"},{"key":"79_CR72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrn2337","volume":"9","author":"XO Breakfield","year":"2008","unstructured":"Breakfield XO, Blood A, Li Y, et al. The pathophysiological basis of dystonias. Nat Rev Neurosci. 2008;9:222\u201343.","journal-title":"Nat Rev Neurosci"},{"key":"79_CR73","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14737175.6.6.863","volume":"6","author":"R Bhidayasiri","year":"2006","unstructured":"Bhidayasiri R, Tarsay D. Treatment of dystonia. Expert Rev Neurother. 2006;6:863\u201386.","journal-title":"Expert Rev Neurother"},{"key":"79_CR74","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s00415-009-5198-z","volume":"256","author":"E Lopez-Laso","year":"2009","unstructured":"Lopez-Laso E, Ochoa-Sepulveda JJ, Ochoa-Amor JJ, et al. Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Cordoba (southern Spain). J Neurol. 2009;256:1816\u201324.","journal-title":"J Neurol"},{"key":"79_CR75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0014-2999(84)90562-4","volume":"20","author":"DJ Pettibone","year":"1984","unstructured":"Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol. 1984;20:425\u201330.","journal-title":"Eur J Pharmacol"},{"key":"79_CR76","first-page":"O58","volume":"S18","author":"N Liow","year":"2013","unstructured":"Liow N, Marianczak J, Kirk E. et al. Gabapentin can improve dystonia severity, transfers, sitting, sleep, mood and pain in children EJPN. 2013;S18:O58\u20132017.","journal-title":"Gabapentin can improve dystonia severity, transfers, sitting, sleep, mood and pain in children EJPN"},{"key":"79_CR77","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/humu.21529","volume":"32","author":"S Brasil","year":"2011","unstructured":"Brasil S, Viecelli HM, Meili D, et al. Pseudoexom exclusion by antisense therapy in 6-pyruvoyl-tetrahydrobiopterin synthase deficiency. Hum Mutat. 2011;32:1019\u201327.","journal-title":"Hum Mutat"},{"issue":"13","key":"79_CR78","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/1871524913666140109113341","volume":"2013","author":"N Jatana","year":"2014","unstructured":"Jatana N, Apoorva N, Malik S, et al. Inhibitors of catechol-O-methyl transferase in the treatment of neurological disorders. Central Nerv Syst Agents Med Chem. 2014;2013(13):166\u201394.","journal-title":"Central Nerv Syst Agents Med Chem"},{"key":"79_CR79","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"80","author":"JL Eberling","year":"2008","unstructured":"Eberling JL, Jaqust WJ, Christine CW, et al. Results from phase 1 safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;80:1980\u20133.","journal-title":"Neurology"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-014-0079-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0079-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0079-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T18:44:31Z","timestamp":1746297871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-014-0079-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1007\/s40272-014-0079-z","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]}}}